Journal of Clinical Oncology
Articles in this Issue
Gender and racial disparities in acute in-hospital outcomes of hairy cell leukemia across the US, 2010-2021.
e19034 Background: Hairy cell leukemia (HCL) has a marked male predominance, with a 4:1 male-to-female ratio in recent studies. Emerging evidence indicate...
Assessing a tumor-agnostic circulating tumor DNA assay for uveal melanoma surveillance and metastatic disease monitoring.
e15037 Background: Uveal melanoma (UM) is a rare and aggressive intraocular malignancy, with up to half of patients developing metastatic disease. Surveil...
Real-world clinical characteristics and outcomes of systemic mastocytosis (SM) patients (Pts) in the era of targeted treatments (Txs): A single-center cohort analysis.
e18588 Background: SM is a rare neoplasm characterized by abnormal mast cell proliferation, driven by a mutation in KIT D816V in >90% of pts. SM encomp...
Clinical utility of [ <sup>18</sup> F]fluoroestradiol (FES) PET/CT to guide second-line treatment decision in patients with ER-positive HER2-negative metastatic breast cancer progressing on first-line endocrine therapy.
1059 Background: Second line treatment options for patients with ER+/HER2- metastatic breast cancer (MBC) after progression on 1 st...
Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes.
6503 Background: Responses to hypomethylating agents (HMAs) in patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocyt...
Genomic features of biliary tract cancers in paired tissues and ctDNA and an integrated molecular classification to predict immunotherapy outcomes.
e16190 Background: Recently, the first-line immunotherapy with immune checkpoint inhibitors (ICIs) significantly improves the prognosis of advanced biliar...
Hematologic and systemic complications of bispecific antibodies: Insights from a National Inpatient Study.
e24121 Background: Bispecific antibodies have revolutionized cancer treatment but are associated with a distinct toxicity profile. This study explores rea...
Prognostic value of time-varying patient-reported symptoms and quality of life in cancer patients receiving chemotherapy.
11044 Background: Prior research has demonstrated that pre-treatment patient-reported outcomes (PROs) predict post-treatment survival. Symptom burden, phy...
Genomic predictors of brain metastases in breast cancer.
2040 Background: Despite therapeutic advances in metastatic breast cancer (MBC), the rising incidence of brain metastases (BM) remains a major challenge,...
A mixed-methods feasibility study to evaluate and assess the clinical utility of multidisciplinary patient-centered information in breast cancer care.
e13594 Background: Patient-centered care (PCC) is an important paradigm shift in healthcare and is considered an essential component in improving the qual...
CLONEVO: Preoperative abemaciclib for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) with molecular response assessment.
4520 Background: Up to 40% of MIBC patients are ineligible to receive standard neoadjuvant cisplatin-based chemotherapy creating a significant unmet need....
Global cervical cancer outcomes and national cancer system characteristics.
5535 Background: Significant global health disparities persist in cervical cancer, with over 85% of cases and deaths occurring in low- and middle-income c...
Burnout, professional fulfillment, and associated factors in academic oncology physicians.
9005 Background: Occupational burnout has negative consequences on the health of individual physicians (MDs), patients, and health care systems. We assess...
Trial in progress: First-in-human study of ATX-559, an oral inhibitor of DHX9, in patients with advanced or metastatic solid tumors, and molecularly defined cancers.
TPS3181 Background: DHX9 is a multifunctional RNA helicase that is involved in the maintenance of genomic stability by resolving DNA/RNA secondary structu...
Non-invasive PD-L1 prediction in NSCLC patients using 3D self-supervised deep learning and radiomics.
3067 Background: Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer for ~85% of all cases. Despite therapeutic advances, prognos...
Versatile-002: Overall survival of HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma patients treated with T cell stimulating immunotherapy PDS0101 and pembrolizumab.
6037 Background: The incidence of HPV-associated head and neck squamous cell carcinoma (HNSCC) continues to rise with over...
Hematologic toxicities with axicabtagene ciloleucel for B cell lymphomas in a majority minority population.
e19011 Background: Chimeric antigen receptor (CAR) T-cell therapy for B-cell lymphomas is increasing in use and predictive tools, like CAR-HEMATOTOX, help...
Rates and predictors of cancer screening in California (CA) prisons.
1607 Background: Cancer is the leading cause of death in state prisons. Patients diagnosed with cancer in prison are more likely to have Stage IV diagnose...
Acute myeloid leukemia (AML) post-high-dose cytarabine (HiDAC) outcomes: Academic versus collaborating community cancer centers.
e18538 Background: The approach to acute myeloid leukemia (AML) management has been evolving towards increased collaboration between academic and communit...
Safety and efficacy of ADG126 (an anti-CTLA-4 masking antibody) in combination with pembrolizumab: Updated results of phase 1b/2 study in advanced MSS CRC.
3579 Background: ADG126 is an anti-CTLA-4 IgG1 masked antibody that is preferentially activated in the tumor upon cleavage of masking peptides in the tumo...
Disease outcomes in immune checkpoint inhibitor colitis: A study comparing initial endoscopic and histological presentation and treatment options.
e24083 Background: Immune-mediated diarrhea and colitis (IMDC) is a common toxicity to immune checkpoint inhibition (ICI) that is becoming increasingly co...
A decade of progress: Trends in 5-year survival across 17 cancer types.
e23262 Background: Advances in cancer detection and treatment have contributed to improvement in survival for many cancer...
A real-world, propensity-matched analysis of second-line (2L) FOLFIRI-Ram versus Ram-Pac in advanced upper gastrointestinal cancers.
4058 Background: Given historically poor outcomes for advanced upper gastrointestinal (UGI) cancers, there is an urgent need for effective 2L treatments....
Real-world data analysis of safety and efficacy of palbociclib in HR positive, HER-2 negative MBC patients, at tertiary care hospital at Middle East, Saudi Arabia.
e13089 Background: In Saudi Arabia, Breast Cancer is the first-ranked cancer among females with a significant increase in incidence over the years, accoun...
Bilateral mastectomy and breast cancer mortality for invasive lobular carcinoma: A SEER-based study.
585 Background: Many women with unilateral breast cancer opt for bilateral mastectomy. While removing the unaffected contralateral breast lowers the risk...